Opening book details…
Can I read 377 Maintenance of normal serum ferritin in a patient with myelodysplastic/myeloproliferative disease-unclassifiable using deferasirox. A case report on EtoBox?
377 Maintenance of normal serum ferritin in a patient with myelodysplastic/myeloproliferative disease-unclassifiable using deferasirox. A case report by M. Gaman; A.M. Vladareanu; I. Voican; D. Cisleanu; H. Bumbea; M. Onisai; A. Alexe; M. Begu; A. Vintilescu; O. Cazaceanu; C. Baluta; A. Ilea; C. Dobrea is a Medicine article available to read on EtoBox.
What is 377 Maintenance of normal serum ferritin in a patient with myelodysplastic/myeloproliferative disease-unclassifiable using deferasirox. A case report about?
Myelodysplastic Syndromes (MDS) are a heterogeneous group of haematopoietic stem cell disorders characterized by cytopenia and hyperplastic bone marrow: in this context red blood cell transfusions represent a life-saving treatment for patients with chronic anaemia. Iron overload is the consequence of a long term transfusion therapy thus it is necessary to prevent this complication by applying a correct iron chelation therapy. Deferasirox is a well tolerated oral iron chelator drug that produces relevant benefits but because of its potential hepatotoxicity it is not recommended for patient with preexisting hepatic diseases. Here we report the case of a 62-year-old man affected by HCV positive cirrhosis and MDS (Refractory Anaemia, IPSS 0.5). Recombinant Erythropoietin therapy was ineffective and a RBC transfusion program was started (2 blood package pro month). At a ferritin serum concentration near 700 ng/mL iron chelation therapy with deferoxamine was proposed in consideration of patient hepatic disease: compliance to subcutaneous injection was very bad, transfusion need increased exponentially until to 2 blood package pro week and serum ferritin concentration reached, in 12 month
Who reads 377 Maintenance of normal serum ferritin in a patient with myelodysplastic/myeloproliferative disease-unclassifiable using deferasirox. A case report?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- M. Gaman; A.M. Vladareanu; I. Voican; D. Cisleanu; H. Bumbea; M. Onisai; A. Alexe; M. Begu; A. Vintilescu; O. Cazaceanu; C. Baluta; A. Ilea; C. Dobrea
- Publisher
- Elsevier Science; Elsevier ; Elsevier Ltd.; Elsevier BV (ISSN 0145-2126)
- Published
- 2011
- Language
- EN
- Field
- Medicine (Health Sciences)